Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Skin Cancer01:30

Skin Cancer

6.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Inflammatory Biomarkers Prognostic Index (IBPI) obtained from standard preoperative blood tests predicts postoperative complications in patients undergoing pelvic exenteration for locally recurrent rectal cancer.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

medRxiv : the preprint server for health sciences·2026
Same author

Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network.

ESMO open·2026
Same author

International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease.

ESMO open·2026
Same author

Defining Standard Data Reporting in Pelvic Exenterations for Non-Rectal Cancers: A Systematic Review of Current Data Reporting.

Cancers·2025
Same author

A comparison of the risk prediction models PERSARC and Sarculator in patients with localized soft tissue sarcoma of the extremities and trunk wall.

ESMO open·2025

Related Experiment Video

Updated: Mar 5, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K

An Update on Non-extremity Soft Tissue Sarcomas.

S J Ford1, L M Almond1, A Gronchi2

  • 1Department of Surgery, University Hospital Birmingham, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|March 24, 2017
PubMed
Summary

Managing soft tissue sarcoma requires specialized care. Centralizing treatment in expert centers improves outcomes, with surgery as the primary curative approach for these challenging cancers.

Keywords:
Neoadjuvant and adjuvant therapiesretroperitoneal soft tissue sarcoma

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K

Related Experiment Videos

Last Updated: Mar 5, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Cancer Management

Background:

  • Soft tissue sarcoma (STS) management is complex and diverse.
  • Centralization of care in high-volume centers has significantly improved patient outcomes.
  • Surgery is the primary potentially curative treatment for STS.

Purpose of the Study:

  • To review current management strategies for soft tissue sarcoma.
  • To highlight challenges in specific STS subtypes like retroperitoneal, head and neck, and breast angiosarcoma.
  • To emphasize the need for continued international collaboration in rare cancer research.

Main Methods:

  • Review of current surgical and therapeutic approaches for soft tissue sarcoma.
  • Discussion of established and emerging treatment modalities.
  • Analysis of management strategies for localized, recurrent, and metastatic disease.

Main Results:

  • Centralized management has revolutionized STS outcomes.
  • Extended resection en bloc is standard for retroperitoneal STS.
  • Neoadjuvant/adjuvant therapies are used case-specifically; their role is under investigation.
  • Management guidelines for recurrences and metastatic disease are established.
  • Secondary angiosarcoma of the breast presents a unique challenge.

Conclusions:

  • Surgery is the cornerstone of potentially curative STS treatment.
  • Specialized centers and international collaboration are crucial for advancing STS care.
  • Further research is needed to establish optimal neoadjuvant/adjuvant therapies and manage rare STS subtypes effectively.